- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02039492
Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension.
Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension
Background: In hypertension, a highly prevalent disease, up to 10-15% of hypertensive patients have uncontrolled blood pressure despite a regimen of ≥ 3 drugs, which is known as resistant hypertension (RH). Cardiovascular prognosis in patients with RH is worse than in controlled hypertensives. Efferent renal sympathetic nerves play an important role in volume homeostasis and blood pressure. A novel minimally invasive technique based on the use of selective radiofrequency renal sympathetic denervation has shown promising preliminary results for the treatment of these patients. On the other hand, some patients with RH could improve their blood pressure control by adding spironolactone, an antagonist of aldosterone receptors.
Objective: To evaluate the efficacy of radiofrequency renal sympathetic denervation in patients with RH, as compared with the addition of spironolactone to the therapeutic regimen at baseline.
Method: interventional, prospective, randomized, open study, of a cohort of 50 patients with RH, with office systolic blood pressure ≥ 150 mmHg and also with 24h systolic blood pressure ≥ 140 mmHg, despite treatment with ≥ 3 drugs in adequate doses, one of them a diuretic, and whitout treatment with either spironolactone or eplerenone. Patients will be randomized (1:1) to renal sympathetic denervation treatment or spironolactone (50mg), performing determination of office blood pressure and 24h-ABPM at pre-randomization, 1, 3 and 6 months, as well as laboratory tests, echocardiography, measurement of carotid intima-media thickness and central blood pressure measurement at pre-randomization and after 6 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar
-
-
Barcelona
-
Hospitalet, Barcelona, Spain, 08906
- Hospital General de l'Hospitalet
-
Terrassa, Barcelona, Spain, 08221
- Hospital Universitari Mutua de Terrassa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged ≥ 18 years and ≤ 80 years.
- Subjects with diagnosed resistant arterial hypertension (office blood pressure ≥ 140 and/or 90 mm Hg despite treatment with at least 3 antihypertensive drugs given at the maximum tolerated therapeutic dosage, being one of them a diuretic), with this therapeutic regimen maintained for at least the last 3 months.
- Office systolic blood pressure ≥150 mm Hg, with confirmation of resistance to treatment by 24h ambulatory blood pressure monitoring, with 24h-systolic blood pressure ≥140 mmHg being required to be included.
- Patients who have freely given informed consent in writing, after the nature of the study and the disclosure of their data have been explained to them.
Exclusion Criteria:
- 1. Secondary hypertension, renovascular disease included with appropriate tests according to investigator criteria (with the exceptions of chronic renal disease and obstructive sleep-apnea syndrome). 2. Inability to perform magnetic resonance angiography or renal CT angiography (contrast allergy). 3. Patients unlikely compliant with treatment (assessed according to Haynes-Sackett test). 4. Patients currently on treatment with an aldosterone receptor blocker (spironolactone, eplerenone) or who had previously received one of such class of drugs and had been withdrawn due to lack of efficacy and/or adverse effects. 5. Stage 3B, 4 or 5 of chronic renal disease (estimated glomerular filtration rate by MDRD equation < 45 mL/min/1.73m2). 6. Pre-randomization serum potassium (K+) level ≥ 5.5 mmol/L. 7. Significant renal vascular anomalies. 8. Pregnant women. 9. Significant valvular heart disease. 10. Major vascular event (myocardial infarction, unstable angina or cerebrovascular disease) < 6 months prior to study enrolment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Denervation
|
|
Active Comparator: B
Treatment with aldactone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in ambulatory 24h-systolic blood pressure (SBP).
Time Frame: From baseline (Visit 0) to Final Examination (6 months).
|
From baseline (Visit 0) to Final Examination (6 months).
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in ambulatory 24h-diastolic blood pressure (DBP), pulse pressure (PP) and heart rate (HR)
Time Frame: From baseline (Visit 0) to Final Examination (6 months).
|
From baseline (Visit 0) to Final Examination (6 months).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Oliveras A, Armario P, Sans L, Clara A, Vazquez S, Molina L, Pareja J, de la Sierra A, Pascual J. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: The DENERVHTA (Denervacion en Hipertension Arterial) study. J Clin Hypertens (Greenwich). 2018 Jan;20(1):69-75. doi: 10.1111/jch.13156. Epub 2018 Jan 5.
- Oliveras A, Armario P, Clara A, Sans-Atxer L, Vazquez S, Pascual J, De la Sierra A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016 Sep;34(9):1863-71. doi: 10.1097/HJH.0000000000001025.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DENERVHTA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resistant Arterial Hypertension
-
National Institute of Cardiology, Laranjeiras,...CompletedArterial Hypertension | Resistant Arterial HypertensionBrazil
-
Heart Center Leipzig - University HospitalCompletedTherapy Resistant Arterial HypertensionGermany
-
Ryazan State Medical UniversityRecruitingResistant Arterial HypertensionRussian Federation
-
National Institute of Cardiology, Laranjeiras,...RecruitingArterial Hypertension | Resistant Hypertension | Microvascular Function | Nitrate SupplementationBrazil
-
Yonsei UniversityTerminatedResistant HypertensionKorea, Republic of
-
National Institute of Cardiology, Laranjeiras,...RecruitingEndothelial Dysfunction | Arterial Hypertension | Resistant Hypertension | Microvascular RarefactionBrazil
-
Ib Abildgaard JacobsenCompletedDiabetes Mellitus | Arterial Hypertension | Hypertension, Resistant to Conventional Therapy
-
AstraZenecaNot yet recruitingResistant Hypertension | Uncontrolled HypertensionVietnam, Korea, Republic of, Philippines, China, Hong Kong, Turkey, Japan, India, Russian Federation, Argentina
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more
-
University Hospital, GenevaCompletedHypertension | Essential Hypertension | Resistant HypertensionSwitzerland
Clinical Trials on Sympathetic Renal Denervation
-
Charles University, Czech RepublicMount Sinai Hospital, New York; General University Hospital, Prague; Na Homolce...UnknownArterial Hypertension | Chronic Renal InsufficiencyCzech Republic
-
Henan Institute of Cardiovascular EpidemiologyCompletedPrimary Aldosteronism Due to Aldosterone Producing AdenomaChina
-
The Second Affiliated Hospital of Chongqing Medical...Chongqing Medical University; Jiangsu Provincial People's HospitalUnknown
-
Vivek ReddyCompletedVentricular TachycardiaUnited States, Czechia, Russian Federation
-
Heart of England NHS TrustCompletedHypertension | Chronic Kidney DiseaseUnited Kingdom
-
Vivek ReddyCompletedVentricular TachycardiaUnited States, Czechia
-
National Institute of Cardiology, Laranjeiras,...CompletedArterial Hypertension | Resistant Arterial HypertensionBrazil
-
The Second Affiliated Hospital of Chongqing Medical...Chongqing Medical University; Jiangsu Provincial People's HospitalUnknown
-
The Second Affiliated Hospital of Chongqing Medical...Chongqing Medical University; Jiangsu Provincial People's HospitalUnknown
-
The First Affiliated Hospital with Nanjing Medical...Unknown